MediPharm Labs (TSX: LABS; OTCQB: MEDIF; FSE: MLZ) has announced that its CEO, David Pidduck, will step down from his role as of January 23, 2026, and that Greg Hunter, the company’s CFO, has been appointed interim CEO.
Mr. Hunter will continue to serve as CFO while leading the company as interim CEO.
In a statement, Chris Taves, chair of the board, commented, “On behalf of the Board and the entire MediPharm Labs team, I want to thank David for his significant contributions. His leadership played a key role in strengthening MediPharm’s financial trajectory and guiding the company through challenging market conditions. We are equally pleased to have a seasoned leader like Greg step into the Interim CEO role during this transition and the Board is confident in his ability to drive execution, operational discipline, and focused growth in the months ahead.”
